The phase II MagnetisMM-3 study of Elrexfio (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
Alison LorenAdam CukerMikkael SekeresThe American Society of Hematology announced the election of three new members to its executive committee for terms starting after the 2025 ASH Annual Meeting on Dec. 6-9 in Orlando.
